Quetiapine versus typical antipsychotic medications for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Suttajit, Sirijit ^a   Srisurapanont, Manit ^a   Maneeton, Benchalak ^a   Maneeton, Narong ^a   Suttajit, Siritree ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PERPHENAZINE; QUETIAPINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

BRIEF PSYCHIATRIC RATING SCALE; CINAHL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COMPARATIVE STUDY; COST OF ILLNESS; DATA EXTRACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEALTH CARE ORGANIZATION; HUMAN; MEDLINE; MENTAL HEALTH SERVICE; MENTAL PATIENT; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PSYCINFO; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70349086620     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007815     Document Type: Review

References (33)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
2. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
3. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-411 (Pubitemid 29476240)
4. Buchanan RW, Carpenter WT. Concept of schizophrenia. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Lippincott Wiliams & Wilkins, 2005.
5. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-690
6. Deeks JJ. Issues in the selection of a summary statistic for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town: The Cochrane Collaboration, 2000.
7. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-629
8. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-2980
9. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-634 (Pubitemid 27387172)
10. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International journal of epidemiology 2002;31(1):140-149 [PUBMED: 11914310] (Pubitemid 34284916)
11. Geddes J, Freemantal N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
12. Goldstein JM, Litwin LC, Sutton EB, Malick JB. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:293-298 (Pubitemid 23278292)
13. Goldstein JM. Preclinical tests that predict clozapine-like atypical antipsychotic actions. Critical issues in the treatment of schizophrenia. International Academy of Biochemical Drug Research 1995;10:95-101
14. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: Data from the health survey for England 1994. American Journal of Epidemiology 1999;149:876-883 (Pubitemid 29196701)
15. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 2006;163:185-194 (Pubitemid 44480836)
16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
18. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1). Archives of General Psychiatry 2006;63:1079-1087 (Pubitemid 44498387)
19. Kane JM. Tardive dyskinesia rates with atypical antipsychotic in adults: prevalence and incidence. Journal of Clinical Psychiatry 2004;65(Suppl 9):16-20.
20. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. New York: Multi-Health Systems Inc, 1986.
21. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry 1994;164(2):141-148
22. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-238
23. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187(4):366-371 (Pubitemid 41442390)
24. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. http: //www.nature.com/mp/journal/vaop/ncurrent/full/4002136a.html (accessed 08 January 2008):1-19. [DOI: 10.1038/sj.mp.4002136]
25. Lieberman JA, Stroup S, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-1223
26. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-252 (Pubitemid 30179844)
27. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 1993;112:299-307
28. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE Technology Appraisal Guidance 2002; Vol.43:1-21.
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812
30. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112(2-3):285-292 (Pubitemid 23278291)
31. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000967.pub2]
32. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92. (Pubitemid 29201269)
33. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. [P85] The Leeds Outcomes Stakeholders Survey (LOSS) Study. 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007. 2007.